ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma

Zhou, Xiang; Xu, Ran; Lu, Tong; Wang, Chenghao; Chang, Xiaoyan; Peng, Bo; Shen, Zhiping; Yao, Lingqi; Wang, Kaiyu; Xu, Chengyu; Shi, Jiaxin; Zhang, Ren; Zhao, Jiaying; Zhang, Linyou*哈尔滨医科大学
Scientific Reports2023-8-16DOI: 10.1038/s41598-023-40592-w
4阅读
引用收藏
分享

摘要

Lung adenocarcinoma (LUAD) is a malignant tumor in the respiratory system. The efficacy of current treatment modalities varies greatly, and individualization is evident. Therefore, finding biomarkers for predicting treatment prognosis and providing reference and guidance for formulating treatment options is urgent. Cancer immunotherapy has made distinct progress in the past decades and has a significant effect on LUAD. Immunogenic Cell Death (ICD) can reshape the tumor's immune microenvironment, contributing to immunotherapy. Thus, exploring ICD biomarkers to construct a prognostic model might help individualized treatments. We used a lung adenocarcinoma (LUAD) dataset to identify ICD-related differentially expressed genes (DEGs). Then, these DEGs were clustered and divided into subgroups. We also performed variance analysis in different dimensions. Further, we established and validated a prognostic model by LASSO Cox regression analysis. The risk score in this model was used to evaluate prognostic differences by survival analysis. The treatment prognosis of various therapies were also predicted. LUAD samples were divided into two subgroups. The ICD-high subgroup was related to an immune-hot phenotype more sensitive to immunotherapy. The prognostic model was constructed based on six ICD-related DEGs. We found that high-risk score patients responded better to immunotherapy. The ICD prognostic model was validated as a standalone factor to evaluate the ICD subtype of individual LUAD patients, which might contribute to more effective therapies.

学科与关键词

关键词
KYOTO ENCYCLOPEDIAEXPRESSIONCANCERGENES
相关
加载中…
  • A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments
    Wang, Chenghao; Lu, Tong; Xu, Ran; Chang, Xiaoyan; Luo, Shan; Peng, Bo; Wang, Jun; Yao, Lingqi; Wang, Kaiyu; Shen, Zhiping; Zhao, Jiaying*; Zhang, Linyou*Journal of Thoracic Disease, 2022, 14(6): 2131-+.被引 2
  • Characterization of lung adenocarcinoma based on immunophenotyping and constructing an immune scoring model to predict prognosis
    Liu, Mengfeng; Xiao, Qifan; Yu, Xiran; Zhao, Yujie; Qu, Changfa*Frontiers in Pharmacology, 2022, 13: 1081244.
  • Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.
    Yi, Ming; Li, Anping; Zhou, Linghui; Chu, Qian; Luo, Suxia*; Wu, Kongming*Cancer Immunol Immunother, 2021, 70(6): 1705-1719.
查看全部 →

发表信息

论文状态
公开发表
期刊
Scientific Reports
发表日期
2023-08-16
卷期
第 13 卷, 第 1 期
DOI
10.1038/s41598-023-40592-w
语言
ENGLISH
成果收录
SCIE

作者

  • Z

    Zhou, Xiang (第一作者)

    2 · harbin med univ

  • X

    Xu, Ran

    2 · harbin med univ

查看全部 14 位作者收起作者
  • L

    Lu, Tong

    2 · harbin med univ

  • W

    Wang, Chenghao

    2 · harbin med univ

  • C

    Chang, Xiaoyan

    2 · harbin med univ

  • P

    Peng, Bo

    2 · harbin med univ

  • S

    Shen, Zhiping

    2 · harbin med univ

  • Y

    Yao, Lingqi

    2 · harbin med univ

  • W

    Wang, Kaiyu

    2 · harbin med univ

  • X

    Xu, Chengyu

    2 · harbin med univ

  • S

    Shi, Jiaxin

    2 · harbin med univ

  • Z

    Zhang, Ren

    2 · harbin med univ

  • Z

    Zhao, Jiaying

    2 · harbin med univ

  • Z

    Zhang, Linyou (通讯)

    2 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417